Firefly Neuroscience (NASDAQ:AIFF) Trading Up 1.6% – Should You Buy?

Firefly Neuroscience, Inc. (NASDAQ:AIFF) shares rose 1.6% during trading on Thursday . The company traded as high as $1.28 and last traded at $1.24. Approximately 71,266 shares were traded during mid-day trading, a decline of 52% from the average session volume of 146,945 shares. The stock had previously closed at $1.22.

Analysts Set New Price Targets

Several brokerages recently weighed in on AIFF. Weiss Ratings upgraded Firefly Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, May 19th. Wall Street Zen upgraded Firefly Neuroscience from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Firefly Neuroscience has a consensus rating of “Sell”.

Firefly Neuroscience Price Performance

The business has a 50 day simple moving average of $1.59 and a 200 day simple moving average of $1.44. The company has a market capitalization of $19.36 million, a price-to-earnings ratio of -1.97 and a beta of 0.55.

Firefly Neuroscience (NASDAQ:AIFF) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.13) EPS for the quarter. Firefly Neuroscience had a negative return on equity of 94.68% and a negative net margin of 565.40%.The firm had revenue of $0.48 million for the quarter.

Hedge Funds Weigh In On Firefly Neuroscience

A number of hedge funds and other institutional investors have recently bought and sold shares of AIFF. Jane Street Group LLC acquired a new position in Firefly Neuroscience in the 4th quarter valued at about $53,000. Vanguard Group Inc. increased its stake in Firefly Neuroscience by 393.3% during the third quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock worth $1,464,000 after purchasing an additional 401,085 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Firefly Neuroscience by 92.9% during the second quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock worth $341,000 after purchasing an additional 58,067 shares in the last quarter. 4.96% of the stock is currently owned by hedge funds and other institutional investors.

About Firefly Neuroscience

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.